Literature DB >> 10681354

Gemifloxacin is effective in experimental pneumococcal meningitis.

A Smirnov1, A Wellmer, J Gerber, K Maier, S Henne, R Nau.   

Abstract

In a rabbit model of Streptococcus pneumoniae meningitis, 5 mg of gemifloxacin mesylate (SB-265805) per kg/h reduced the bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as 10 mg of ceftriaxone per kg/h (Deltalog CFU/ml/h +/- standard deviation [SD], -0.25 +/- 0.09 versus -0.38 +/- 0.11; serum and CSF concentrations of gemifloxacin were 2.1 +/- 1.4 mg/liter and 0.59 +/- 0.38 mg/liter, respectively, at 24 h). Coadministration of 1 mg of dexamethasone per kg did not affect gemifloxacin serum and CSF levels (2.7 +/- 1.4 mg/liter and 0.75 +/- 0.34 mg/liter, respectively, at 24 h) or activity (Deltalog CFU/ml/h +/- SD, -0.26 +/- 0.11).

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10681354      PMCID： PMC89762          DOI： 10.1128/AAC.44.3.767-770.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Trovafloxacin delays the antibiotic-induced inflammatory response in experimental pneumococcal meningitis.

Authors:  R Nau; G Zysk; H Schmidt; F R Fischer; A K Stringaris; K Stuertz; W Brück
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

2.  Comparative distribution of quinolone antibiotics in cerebrospinal fluid and brain in rats and dogs.

Authors:  T Ooie; H Suzuki; T Terasaki; Y Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

3.  Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to beta-lactam antibiotics, rifamycins, trovafloxacin, and quinupristin-dalfopristin.

Authors:  K Stuertz; H Schmidt; H Eiffert; P Schwartz; M Mäder; R Nau
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

4.  Moxifloxacin in the therapy of experimental pneumococcal meningitis.

Authors:  H Schmidt; A Dalhoff; K Stuertz; F Trostdorf; V Chen; O Schneider; C Kohlsdorfer; W Brück; R Nau
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

5.  Anti-inflammatory treatment influences neuronal apoptotic cell death in the dentate gyrus in experimental pneumococcal meningitis.

Authors:  G Zysk; W Brück; J Gerber; Y Brück; H W Prange; R Nau
Journal:  J Neuropathol Exp Neurol       Date:  1996-06       Impact factor: 3.685

6.  Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis.

Authors:  C Cabellos; J Martinez-Lacasa; A Martos; F Tubau; A Fernández; P F Viladrich; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

7.  The fluctuations of neuron-specific enolase (NSE) levels of cerebrospinal fluid during bacterial meningitis: the relationship between the fluctuations of NSE levels and neurological complications or outcome.

Authors:  S Inoue; H Takahashi; K Kaneko
Journal:  Acta Paediatr Jpn       Date:  1994-10

8.  Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin.

Authors:  R Nau; M Kinzig; T Dreyhaupt; H Kolenda; F Sörgel; H W Prange
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

9.  Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits.

Authors:  R Nau; T Schmidt; K Kaye; J L Froula; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

10.  Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis.

Authors:  I Lutsar; I R Friedland; L Wubbel; C C McCoig; H S Jafri; W Ng; F Ghaffar; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191
View more
  4 in total

1.  Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.

Authors:  A P MacGowan; C A Rogers; H A Holt; M Wootton; K E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 2.  Bacterial meningitis in children: critical review of current concepts.

Authors:  Ram Yogev; Judith Guzman-Cottrill
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Gemifloxacin.

Authors:  M N Lowe; H M Lamb
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

4.  Fluoroquinolones in the Treatment of Meningitis.

Authors:  Philippe Cottagnoud; Martin G. Täuber
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.